Treatment of Localized Prostatic Carcinoma Using the Transrectal Ultrasound Guided Transperineal Implantation Technique

Vijverberg, P.L.M.; Kh, Kurth; Blank, L.E.C.M.; Dabhoiwala, N.F.; Reijke, T. H. M. de; Koedooder, Kees

doi:10.1159/000474797

Cited by 22 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysuria was the most frequent obstructive symptom in the present patients, as also noted by others [2,15], whereas Nag et al [3] reported dysuria in almost 90%, using 103 Pd. Likewise, the present patients often complained of a weak stream but there were no cases of acute urinary retention, reported in up to 22% by others [17].…”

Section: Discussionsupporting

confidence: 68%

Urinary morbidity after ¹²⁵I brachytherapy of the prostate

et al. 2003

View full text Add to dashboard Cite

RESULTSThirty-eight (76%) patients developed urinary disorders, but severe urinary complications were exceptional. The International Prostate Symptom Score (IPSS) changed significantly during the first and third month after implantation and then improved during the sixth month. Concomitantly, the maximum and the average urinary flow rate deteriorated significantly. The variations in postvoid residual were less significant. An initial IPSS of >8 and previous a -blocker treatment were identified as significant predictive factors of urinary morbidity, as were the TPBT dose received by 90% of the target volume and by 30% of the urethra, and the volume of prostate receiving 144 Gy. CONCLUSIONUrinary morbidity after TPBT is frequent but rarely exceptionally severe; patients must therefore be given full information. Patients with a higher initial IPSS or having had previous a -blocker treatment, with their associated dosimetric factors, are at greater risk of these urinary morbidity. KEYWORDS brachytherapy, prostate cancer, urinary morbidity OBJECTIVETo assess urinary morbidity within the first 6 months after transperineal prostate brachytherapy (TPBT) with 125 I for localized prostate adenocarcinoma. PATIENTS AND METHODSBetween September 2000 and July 2001, 50 consecutive patients with favourable earlystage prostate cancer were treated with TPBT. Clinical and objective investigations, including uroflowmetry and postvoid residual urine measurements, were evaluated for short-term urinary morbidity; predictive factors were also sought.

show abstract

Section: Discussionsupporting

confidence: 68%

Urinary morbidity after ¹²⁵I brachytherapy of the prostate

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Review of the contemporary transperineal experience using template and image guidance is still ongoing. [22][23][24][25][26][27][28][29][30][31][32][33] While some early studies 22,31 indicate significant proportions of tumor-positive biopsies postimplantation and/or distant metastases, most of the large published series [24][25][26]29 have shown PSA-based control rates comparable to prostatectomy or external beam radiation. A notable study by Vijverberg et al 33 examined biopsy findings postimplantation and the quality of the implant in terms of the minimum dose delivered to the prostate.…”

Section: Introductionmentioning

confidence: 99%

Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64

et al. 1999

View full text Add to dashboard Cite

There is now considerable evidence to suggest that technical innovations, 3D image-based planning, template guidance, computerized dosimetry analysis and improved quality assurance practice have converged in synergy in modern prostate brachytherapy, which promise to lead to increased tumor control and decreased toxicity. A substantial part of the medical physicist's contribution to this multi-disciplinary modality has a direct impact on the factors that may singly or jointly determine the treatment outcome. It is therefore of paramount importance for the medical physics community to establish a uniform standard of practice for prostate brachytherapy physics, so that the therapeutic potential of the modality can be maximally and consistently realized in the wider healthcare community. A recent survey in the U.S. for prostate brachytherapy revealed alarming variance in the pattern of practice in physics and dosimetry, particularly in regard to dose calculation, seed assay and time/method of postimplant imaging. Because of the large number of start-up programs at this time, it is essential that the roles and responsibilities of the medical physicist be clearly defined, consistent with the pivotal nature of the clinical physics component in assuring the ultimate success of prostate brachytherapy. It was against this background that the Radiation Therapy Committee of the American Association of Physicists in Medicine formed Task Group No. 64, which was charged ͑1͒ to review the current techniques in prostate seed implant brachytherapy, ͑2͒ to summarize the present knowledge in treatment planning, dose specification and reporting, ͑3͒ to recommend practical guidelines for the clinical medical physicist, and ͑4͒ to identify issues for future investigation.

show abstract

“…M Sanchez-Chapado, J C Angulo et al 14 found "the accuracy of TRUS for detection of ECE to be around 60%". However P L Vijverberg, M C Giessen et al 15 found "sensitivity and specificity of TRUS to be 43% and 91% respectively", for detection of ECE; Colombo T, Schips L, Augustin H, et al 1 found "sensitivity, specificity, positive predictive values as 41.2%, 81.8% and 36.8% respectively"; J C Presti, H Hricak et al 3 found, "sensitivity (48% ), specificity (71% ), positive predictive value (50%), and negative predictive value (69%)"; Maria Inês Novis, Ronaldo Hueb Baroni et al 5 found "sensitivity, specificity, PPV and NPV values as 33.3%, 92%, 14.3% and 97.2% for transrectal ultrasound in the detection of ECE". All these studies show the sensitivity of TRUS to be lower as compared to our study.…”

Section: Trans Rectal Ultrasound (Trus)mentioning

confidence: 99%

Role of transrectal ultrasound and MRI in the diagnosis and localisation of carcinoma prostate - A comparison of diagnostic efficacy of trus versus MRI

Satish,

Gowda

et al. 2024

PJMS

View full text Add to dashboard Cite

In this study, we wanted to correlate the findings of TRUS and MRI with regard to the diagnosis and localization of carcinoma prostate and local staging of carcinoma prostate. Our study included 43 men, with age ranging from 49 to 76 years. They underwent TRUS, MRI and TRUS guided twelve core biopsies after being suspected with prostate cancer based on high PSA values (greater than 4.0 ng /ml) or abnormal DRE findings. This study was conducted from April 2018 -June 2019. Imaging findings were confirmed with histopathology. TRUS used for the detection of malignancy had sensitivity, specificity, PPV and NPV as 69.70%, 80 %, 92% and 44.44 % respectively. The values were 63.16%, 83.33%, 75.00%, and 74.07% for the sensitivity, specificity, PPV and NPV of TRUS respectively for the detection of ECE. rnFor the detection of malignancy, the sensitivity, specificity, PPV and NPV of MRI was 87.88%, 70%, 90.63% and 63.64% respectively and 85.71%, 89.66%, 80.00% and 92.86% for the sensitivity, specificity, PPV and NPV of MRI respectively for detection of SVI. For detection of extracapsular extension (ECE), MRI had sensitivity, specificity, PPV and NPV of 78.95%, 83.33%, 78.95% and 83.33% respectively. When compared to TRUS, MRI is more useful in the diagnosis and accurate staging of prostate cancer. MRI can improve the false-negative biopsies resulting due to the inability of TRUS in detection of abnormal areas.

show abstract

Treatment of Localized Prostatic Carcinoma Using the Transrectal Ultrasound Guided Transperineal Implantation Technique

Cited by 22 publications

References 13 publications

Urinary morbidity after ¹²⁵I brachytherapy of the prostate

Urinary morbidity after ¹²⁵I brachytherapy of the prostate

Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64

Role of transrectal ultrasound and MRI in the diagnosis and localisation of carcinoma prostate - A comparison of diagnostic efficacy of trus versus MRI

Contact Info

Product

Resources

About

Treatment of Localized Prostatic Carcinoma Using the Transrectal Ultrasound Guided Transperineal Implantation Technique

Cited by 22 publications

References 13 publications

Urinary morbidity after 125I brachytherapy of the prostate

Urinary morbidity after 125I brachytherapy of the prostate

Permanent prostate seed implant brachytherapy: Report of the American Association of Physicists in Medicine Task Group No. 64

Role of transrectal ultrasound and MRI in the diagnosis and localisation of carcinoma prostate - A comparison of diagnostic efficacy of trus versus MRI

Contact Info

Product

Resources

About

Urinary morbidity after ¹²⁵I brachytherapy of the prostate

Urinary morbidity after ¹²⁵I brachytherapy of the prostate